Sentinext Therapeutics was established in 2008 by Dr Jane Cardosa, internationally renowned for her work on diseases and viruses, including, Hand, Foot and Mouth Disease (HFMD), Dengue and viral encephalitis.
She established Sentinext Therapeutics to develop superior vaccines that protect against infectious viral diseases where there is a significant unmet medical need, especially in the Asia Pacific region.
One of the major issues that has emerged in the Asia Pacific region is severe complications and death of children suffering from HFMD due to the emergence of a relatively new virus - human EV71 - which can progress to disease with complications affecting the central nervous system.
Sentinext has developed a platform for generating EV71 VLPs using recombinant baculoviruses containing all the capsid proteins needed to create a particle that mimics the actual virus without containing any viral genome. This ensures that Sentinext’s VLPs are natural and not infectious.
Sentinext has developed a system to produce very high yields of EV71 VLPs which have generated a strong neutralizing antibody response in mice and monkeys. This innovative VLP platform can also be applied to other enteroviruses including polioviruses and Coxsackieviruses.
In early 2016, Sentinext Therapeutics will enter phase I clinical trials for its EV71 VLP vaccine, to be followed by clinical trials to show proof of concept of efficacy against HFMD in children.
DEVELOPING POLIOVIRUS VLPs
In 2011, Sentinext Therapeutics was awarded a “Grand Challenges Explorations” (GCE) grant from the Bill and Melinda Gates Foundation (BMGF) to test whether its innovative VLP platform – as a Best-in-Class approach – would be an option for a new and safe vaccine to protect the world’s population from polio.
Sentinext’s poliovirus VLPs will be a ground-breaking approach to post-eradication management of the disease allowing for a safe and efficacious polio vaccine which will have absolutely no risk to the environment and will provide the means to protect children in case of re-emergence.
Sentinext is currently collaborating with Professor Ian Jones at the University of Reading to continue to develop its poliovirus VLPs.